Constitutional genetic variation at the human aromatase gene (*Cyp19*) and breast cancer risk

N Siegelmann-Danieli* and KH Buetow†

Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA, USA

Summary The activity of the aromatase enzyme, which converts androgens into oestrogens and has a major role in regulating oestrogen levels in the breast, is thought to be a contributing factor in the development of breast cancer. We undertook this study to assess the role of constitutional genetic variation in the human aromatase gene (*Cyp19*) in the development of this disease. Our genotyping of 348 cases with breast cancer and 145 controls (all Caucasian women) for a published tetranucleotide repeat polymorphism at intron 4 of the *Cyp19* gene revealed the presence of six common and two rare alleles. Contingency table analysis revealed a significant difference in allelic distribution between cases and controls (χ^2 5df = 13.52, P = 0.019). The allele measuring 171 bp was over-represented in cases; of 14 individuals homozygous for this allele, 13 were cases. These individuals had a higher incidence of cancer in family members and an earlier age at diagnosis than other cases. In sequencing *Cyp19*'s coding exons and regulatory regions, we discovered a perfect association between a silent polymorphism (G→A at Val80) and the high-risk genotype. Our conclusion is that constitutional genetic variation at the *Cyp19* locus is associated with the risk of developing breast cancer, with the 171-bp allele serving as the high-risk allele.

Keywords: breast cancer; aromatase gene; oestrogens; *Cyp19*

This work examined the role of constitutional genetic variation at a candidate locus, the human aromatase gene (*Cyp19*), in breast cancer development. *Cyp19* encodes for a cytochrome P450 aromatase, an enzyme catalysing the conversion of androgens into oestrogens (Tan and Muto, 1986; Mendelson et al, 1990). Aromatase activity has been demonstrated in multiple tissues including normal and transformed breast tissues (James et al, 1987; Bulun and Simpson, 1994; Santen et al, 1994; Sasano et al, 1994). Several reports suggest a positive feedback between breast tumours and aromatase activity in neighbouring breast parenchyma (James et al, 1987; Sasano et al, 1994; Schmidt and Loffler, 1994; Purohit et al, 1995). This suggests that local oestrogen production within the breast, by the aromatase enzyme, might affect breast cancer development and progression.

The *Cyp19* gene has been previously characterized and mapped to chromosome 15q21.1 (Chen et al, 1988). It is a single copy gene which spans over more than 70 kb, with the translated exons II–X spanning over only 30 kb (Harada, 1988; Harada et al, 1990; Toda et al, 1990). Multiple non-translated exons I are located at the 5' region and control the gene expression in a tissue-specific manner and under complex hormonal regulation (Mahendroo et al, 1993; Means et al, 1991; Harada et al, 1993; Toda and Shizuta, 1993; Honda et al, 1994; Toda et al, 1995; Zhao et al, 1995) (Figure 1). These regulatory regions might also participate in the pathogenesis of malignant breast transformation because different exons I are found to control aromatase expression in normal breast (exon I.4) and during malignant transformation (exon I.3 and promoter II) (Agarwal et al, 1996; Utsumi et al, 1996; Zhou et al, 1996a, b).

The open reading frame is identical in all expressing tissues examined to date and consists of 1509 bp encoding a 503-amino-acid residue protein (Corbin et al, 1988; Harada, 1988; Means et al, 1989). Rare syndromes of complete aromatase deficiency have been described at the DNA sequence level (exon 6/intron 6 splicing mutation with an 87-bp insert described by Harada et al, 1992; a compound heterozygosity state for exon 10 mutations described by Conte et al, 1994). A common, high heterozygosity tetranucleotide simple tandem repeat polymorphism (STRP) in intron 4 has been previously described (Polymeropoulos et al, 1991). It is not known, however, whether genetic polymorphism at this locus is associated with specific phenotype.

In this study, association-based gene mapping methods were used to assess whether the *Cyp19* locus plays a role in determining breast cancer risk. Patterns of constitutional genetic variation were measured at the *Cyp19* intron for STRP (modified after Polymeropoulos et al, 1991) and contrasted in cases with breast cancer and healthy controls. To identify whether specific STRP alleles were in linkage disequilibrium with other mutations, *Cyp19* coding and regulatory regions were sequenced in cases identified with the high-risk genotype and controls with the putative low-risk genotype.

PATIENTS AND METHODS

Study population

Participants were consecutive non-related Caucasian women, aged 27–79 years old, living in the greater Philadelphia region and attending Fox Chase Cancer Center (FCCC) breast cancer and cancer-screening clinics and FCCC network hospitals (cancer clinics and non-cancer-related clinics), or hospital employees,

Received 15 December 1997

Revised 21 April 1998

Accepted 11 March 1998

Correspondence to: N Siegelmann-Danieli, Department of Oncology, Rambam Medical Center, PO Box 9602, Haifa 31096, Israel

Authors' current affiliations: *Department of Oncology, Rambam Medical Center, PO Box 9602, Haifa 31096, Israel; †Fox Chase Cancer Center, 7701 Burdette Avenue, Philadelphia, PA 19111, USA.

Figure 1 *Cyp 19* coding region and major non-translated tissue-specific exon 1 in the placenta, adipose and ovarian tissues that were sequenced in cases with a high-risk genotype and controls with a low-risk genotype. Points to note: (1) coding regions: exons 2–10; (2) placenta-specific major exon 1: exon I.1; (3) regulatory elements for exon I.1: cis1/2 (Toda et al, 1995); (4) adipose-specific exon 1: exons I.4, exon I.3, promoter II (the 5' region to exon 2, →P); [Overlapping primers were designed to include the non-translated exons and their 5' regulatory regions (Zhao et al, 1995, 1996a, b).] exon I.4 controls aromatase expression in normal breast adipose tissue, and exon I.3 and promoter II are up-regulated during malignant transformation; and (5) ovarian-specific exon I: promoter II (→P)

from 1988 to 1994. Participation was voluntary, and participants were required to sign an institutionally-approved consent form. Cases were women diagnosed with breast cancer, controls were women with no history of cancer other than non-melanomatous skin cancer or cervical carcinoma in situ. The study group included 348 cases and 145 controls with a similar age distribution: mean age (at diagnosis for cases and at enrolment for controls) of 54.3 and 54.9 years old and median age of 53.5 and 55 years old in cases and controls respectively.

Information on tumour characteristics at time of diagnosis was abstracted retrospectively through review of the computerized medical charts. This review was blind with respect to the outcome of any genetic test used for this study. The following data were obtained: staging status according to the TNM system (American Joint Committee on Cancer, 1992); histopathological type and grade; fibrocystic changes and ductal carcinoma in situ (DCIS); oestrogen and progesterone receptor status; bilateral breast cancer; and clinical or gross-pathological multifocal tumours. These data were available for about 50–80% of participants. In 88%, staging information was based on pathological finding at time of diagnosis; in only 12% was it clinically based. The majority of cases had invasive breast tumors (96%), with 84% diagnosed with T1 and 2 (tumour up to 5 cm in greatest dimension) and 12% with T3 and 4 (tumours more than 5 cm in greatest dimension or with dermal/chest wall invasion). Axillary nodal metastases were noted in 38% of cases; in 74%, the histology type was ductal carcinoma and in 8% it was lobular carcinoma. The rest had either both or adenocarcinoma not otherwise specified. Histology grade was well to moderate in 54% and steroid receptors were positive in 63% of cases. The cases in our population had a relatively low incidence of DCIS in comparison with 1991 National Institute of Health Surveillance, Epidemiology, and End Results (SEER) data (4% vs 12.4% respectively). In other respects, the cases were comparable to women newly diagnosed with invasive breast cancer in the United States during the study period (Ries et al, 1994).

Information on family history of cancer was available for 262 cases. A positive family history of breast cancer in a first-degree family member was noted in 60 families (23%). Family history consistent with hereditary breast or breast and ovarian syndromes

Table 1 Primers used to sequence *Cyp19* coding regions and major non-translated exons I that are transcribed in adipose, ovarian and placenta tissues (see also Figure 1)

Exon	Primer sets	Forward oligonucleotide	Reverse oligonucleotide	Annealing temperature (°C)	Size (bp)
Cis1	Cis1	CCAGGAATCAGGAGACCT	TTCTAGGAGAAGCTGAGAAAGA	56	303
Cis2	Cis2	GGATTTTTTGGCACAGGAG	CCCAGTCATCATATCCCCAC	58	278
I.1	Exl.1	AGAGAGGAAGAAGAATCTGAAC	ATCTACCTGGAAAGAGTGTCTG	59	310
	Exl.1a	AAGACACAGGGTTCAGGGAGT	GCAGTGTTTTCCCTCTGCTC	66	321
	Exl.1b	AGCCTTCTGGGCTTCTCTTT	CTTCTCTCTTTGTGCAGCA	58	514
I.4	Exl.40	TCCTGAAAGAATGTCAGCTCG	GCAGGGGTGTCAGAGTTTTC	60	155
	Exl.41	AGTAGTGCAATTTGAGAATGGG	AGCTGAAGACGACAGATGAA	57	347
	Exl.42	TCCTTGATCCCAGGAAACAG	TGCCAAGCACAGAACAGTC	57	334
	Exl.43	AAGGAATGGTGAGAGTTTGG	TTTTTGTGCTGACTGTGG	56	420
I.3	Exl.3	GATTTGGCTTCAAGGGAAGA	ATCGGGTTCAGCATTCCAA	62	480
2	Ex2	GGACTCTAAATTGCCCCCTC	ATGATGGACCAAAATCCCAA	57	246
3	Ex3	AGTAACACAGAACAGTTGCA	GCAATGTTAGATTCTGGGG	55	374
4	Ex4	AGCTGCCTCCTAGTCAAAATG	TTACAGTGAGCCAAGGTCGT	65	414
	Ex4a ^a	AGCTGCCTCCTAGTCAAAATG	TACCTTTCATAAAGAAGGGTCG	58	238
5	Ex5	TCTGTAGGCTGATTCTCTG	GGTCAAGATGTGAGAGTGA	53	242
6	Ex6	CTCAGAGCAACCTTCTTAGGC	AGAAAAGTTACCTGAGAGGCC	56	288
7	Ex7	CATGGCAAATAAATCTGTTTCG	GGGCTATTTGGATTGGGATT	56	333
8	Ex8 ^b	AGTGTACCTCCCCTCATTT	GATATCAGATTCTTAGGAC	52	324
9	Ex9	CCACAGGTGAGAGAGACATAA	GCTCCTTACATTCTTTGCAA	57	257
10 ^c	Ex10.1	TGAATCAACAGAGACTGAGTG	ACTCTTGGCCTCTGCTTTTTT	57	538
	Ex10.2	TCTGCTCCTGTTTACACCCAG	ACACTAGCAGGTGGGTTTGG	56	285
	Ex10.3	TGATTAGAAAGACCAGGCCA	TCTCTTGGTTAGCCACACTAA	56	489
	Ex10.4	ATTATTAGGGCCCTGTGTCT	TCTCTTGGTTAGCCACACTAAT	59	480
	Ex10.5	TGAATCATTGTATGTGGTCATG	TTTCAGGGAGTTACACTGTCA	53	279

^aEx4a was designed to amplify exon 4 and its immediate flanking regions, whereas primers Ex4 amplified also the intron 4 STRP region. ^bThe sequencing products in both cases and controls did not include the 35-bp region located at –80 bp to –45 bp upstream to exon 8 according to gene bank data. ^cPrimers Ex10.1 were used to amplify the coding region of exon 10, and Ex10.2 to 10.5 to amplify its 3' UTR up to the second polyadenylation site.

(having two or more affected first-degree relatives with these cancers; affected first- and second-degree relatives on the maternal side of the family; or two affected second-degree relatives on paternal side of the family) was evident in 26 families (10%).

Genetic analysis

DNA extraction from peripheral nucleated cells was performed using a salt extraction protocol (Miller et al, 1988). The STRP at intron 4 of the *Cyp19* gene was typed using primers described by Polymeropoulos et al (1991). The polymerase chain reaction (PCR) was performed on 15 ng of genomic DNA using 2.5 pmol of each *Cyp19* primer. Amplification was carried out for 35 cycles (denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s). The products were denatured (5 min at 95°C) and applied to a 6% denaturing acrylamide gel along with size markers. Dried gels were exposed to radiographic films for 48–72 h.

To confirm Mendelian transmission and the allele calling for the STRP, the CYP19 locus was genotyped on the CEPH reference pedigree panel. A total of 90 independent individuals were genotyped from 45 families. A subset of 12 pedigrees was genotyped for all three generations of the families. Genetic mapping methods were carried out as described previously (Buetow, 1996).

To rigorously determine absolute allele sizes in bp, samples from 78 individuals were also genotyped using the ABI 373 fluorescent electrophoresis system. Three fluorescent deoxyuridine triphosphates (dUTP) were added to the PCR reaction described above (Prism dUTP Set, Applied Biosystems, USA), each to a different DNA sample. A lambda phage DNA digested with *Pst*I was labelled with a fourth fluorescent dye and used as internal lane standard. The products were pooled and run on a 6% denaturing acrylamide gel with an internal size standard in each lane. They were analysed using the Genotyper software to determine allele size, identification and peak height. Contingency table analysis was used to compare allele and genotype distribution between cases and controls and to assess allele distribution and tumour characteristics.

Sequence analysis

Sequencing was performed on the ABI 377 using the ABI Prism Dye terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase, FS (Applied Biosystems). Primers were designed using the Primer program (v0.5) for the regions shown in Figure 1 and are listed in Table 1. PCR products of sizes

less than 300 bp were sequenced on 36-cm plates, whereas products larger than 300 bp were sequenced on 48-cm plates. The sequence generated by the ABI 377 instrument was analysed using a combination of software tools including ABI's sequence analysis software (for conversion of gel files to electropherograms), Phred/Phrap (for base determination and sequence assembly) and Consript (for mutation/polymorphism identification within sequence assemblies). Phred and Phrap were provided courtesy of P Green, University of Washington, USA.

RESULTS

Genetic mapping of the *Cyp19* locus

Genotyping was first conducted on the CEPH reference panel. The CYP19 locus was observed to be in Hardy–Weinberg equilibrium and transmitted in a Mendelian fashion. To confirm that the locus under investigation was indeed the CYP19 locus previously described in the literature, the STRP was genetically mapped using the CEPH genotype resource (Buetow, 1996). Significant pairwise linkage was observed between the CYP19 STRP and six markers localized to human chromosome 15 (D15S220, D15S117, D15S125, D15S131, D15S114 and D15S175). Complete linkage (no recombination) was observed between CYP19 and D15S220 (lod score = 16.26). Multipoint linkage analysis localized CYP19 with lod 3 support to the interval defined by loci D15S172 and D15S117 in the Cooperative Human Linkage Center's (CHLC) version 4.0 recombination–minimization map (<http://WWW.CHLC.ORG>). The maximum likelihood location for the locus was in the 3.5-cM interval defined by D15S648–D15S117, and is in agreement with prior mapping to 15q21.1 (Chen et al, 1988).

Cyp19 allele's distribution in cases and controls

Cases and controls analysed by autoradiography showed six common alleles with sizes ranging from 168 bp to 191 bp (allele 1, 168 bp; allele 2, 171 bp; allele 3, 175 bp; allele 4, 183 bp; allele 5, 187 bp; allele 6, 191 bp). Two rare alleles of sizes 179 bp and 195 bp were also identified in two cases and three controls. Table 2 summarizes the frequencies of the six common alleles in the study participants (692 alleles for cases and 284 alleles for controls). The 171-bp allele (allele 2) was over-represented in cases (odds ratio 1.47, confidence interval 0.993–2.17), whereas the 191-bp allele (allele 6) was over-represented in controls. Contingency table analysis revealed the allelic distribution to be significantly different between cases and controls (χ^2 5df = 13.52, P = 0.019). Inclusion of the two rare alleles in the analysis did not significantly affect the results (χ^2 7df = 16.07, P = 0.024).

To rigorously determine absolute allele size in base pairs, we genotyped samples from 78 individuals using the ABI 373 automated electrophoresis apparatus and software. As expected, the results for the six common alleles were 100% concordant with those obtained by autoradiography. Genotyping results by both methods are shown in Figure 2 (autoradiography results from the CEPH reference panel in A, and genotyping *Cyp19* locus on the ABI 373 in B).

Cyp19 genotype's distribution in cases and controls: identifying a high-risk genotype

Genotype analysis revealed that homozygotes for the 171-bp allele were 5.4 times more likely to be in the cases group, with a

Table 2 Allele frequencies in Caucasian women (expressed as percentage of a specific allele in the total group) for 692 chromosomes of cases and 284 chromosomes of controls^a

Allele no.	Allele size (bp)	Frequency in controls	Frequency in cases
1	168	0.334	0.327
2	171	0.134	0.185
3	175	0.116	0.118
4	183	0.018	0.019
5	187	0.345	0.335
6	191	0.053	0.016

^aChi-squared analysis revealed the allele distribution to be significantly different between cases and controls at P = 0.019, χ^2 5df = 13.52.

A

B

Figure 2 Genotyping for the *Cyp19* locus. (A) *Cyp19* genotyping by the autoradiography method: CEPH family no. 1354. (B) Genotyping *Cyp19* locus on ABI 373 sequencer

frequency of 3.78% and 0.70% in cases and controls respectively. Moreover, of 14 study participants homozygous for the 171-bp allele, 13 were cases. All 13 cases had unilateral invasive breast tumours, with comparable tumour characteristics to those of other cases (data not shown). They had a median age at diagnosis 5.5 years younger than other cases (mean and median age at diagnosis were 50.9 and 48 years in cases homozygous for the 171-bp allele,

54.2 and 53.5 years in total case group respectively), but this difference was not statistically significant. The only control individual homozygous for the 171-bp allele was 46 years of age at time of inclusion.

Family data were available for 13 of these individuals and are summarized in Table 3. In ten individuals, there was a first-degree family relative with a solid cancer or leukaemia. In six cases, there was a family history of breast cancer (in families 6, 9 and 10 it is suggestive of putative hereditary breast or breast/ovarian cancers). Although individuals homozygous for the 171-bp allele had a higher prevalence of a positive history of breast cancer in a first-degree family relative compared with other cases, this difference was not statistically significant ($P = 0.12$).

Two additional genotypes were disproportionately distributed among cases and controls. Heterozygotes for the 171-/187-bp alleles were 1.85 times more likely to be in the cases group (frequency of 13% and 7% in cases and controls respectively), and heterozygotes for the 187-/191-bp alleles were five times more likely to be controls (frequency of 1.12% and 5.63% in cases and controls respectively). No participants were homozygous for the 191-bp allele, which was observed to be over-represented in controls (Table 2). Other genotypes were either rare (frequency of less than 1.5%) or occurred with a similar frequency among cases and controls.

We concluded that the 171-bp allele represents a high-risk allele. Individuals homozygous for this allele are considered to carry a high-risk genotype. Heterozygotes for the 187-/191-bp alleles are considered to carry a putative low-risk genotype.

No significant association was observed between the occurrence of one or more copies of the 171-bp allele and the following cases' characteristics: menopausal status (using age 50 as a cut-off point); invasive vs non-invasive tumours; tumour size (T-stage 1 and 2 vs 3 and 4); lymph node involvement; multifocal or bilateral tumours; histology type and grade; background histology changes and receptor status.

Sequencing results

To identify whether specific STRP allele variants were in linkage disequilibrium with other mutations at the *CYP19* gene, sequencing results were contrasted for cases with the high-risk STRP genotype (homozygous for the 171-bp allele) and controls with the low-risk STRP genotype (heterozygotes for the 187-/191-bp alleles). Sequencing efforts were targeted at the coding regions of *Cyp19* (including the 3' UTR of exon 10 up to the second polyadenylation site), and at major non-translated regulatory exons I for adipose, ovarian and placenta tissues (see Figure 1). At least five individuals in each group were sequenced. Sequence variants confirmed by the reverse sequence were extended to additional individuals (up to 12 cases and the one control) homozygous for the 171-bp allele (DNA for one high-risk case was not available for sequencing reactions).

Table 4 summarizes the identified *Cyp19* sequence variants and their frequencies among cases with the high-risk genotype and controls with the low-risk genotype (the 12 cases and one control carrying the high-risk genotype are reported together, as they displayed the same sequence variants). Of identified sequence variants, two occurred in coding exons of the *Cyp19* gene, and were detected only among individuals carrying the high-risk genotype. The first, a silent variation at exon 3 (G→A, Val80), occurred in its homozygous state in all individuals carrying the high-risk

Figure 3 G→A variation at exon 3 of the *Cyp19* gene (silent polymorphism at Val80) which appeared in complete association with the high-risk genotype

Table 3 Family history of cancer in 14 Caucasian women homozygous for the 171-bp allele^a

Individual's number	Age (years)	First degree	Second or more degree
Cases			
1	52	Mother, breast cancer at 51 Father, lung cancer at 62	
2	51		M uncle, lung cancer P uncle, lung cancer
3	58	Brother, lung cancer at 55	M grandmother's brother, prostate cancer at 86
4	47	Mother, breast cancer at 30	M grandmother, leukaemia at 60 M grandmother's brother, cancer at 89
5	60	Brother, leukaemia at 59 Brother, head and neck cancer	
6	59	Sister, ovarian cancer at 49 Sister, breast cancer at 50 Brother, lung cancer at 59 Brother, lung cancer at 66	
7	72	Daughter, breast cancer at 49	
8	45	(Not known)	(Not known)
9	48		P aunt, breast cancer at 70 P cousin, breast cancer at 28 P cousin, breast cancer at 30 P uncle, colon cancer P uncle, lung cancer P uncle, CNS cancer P uncle, spine cancer M great aunt, breast cancer
10	47	Mother, breast cancer	
11	36	Father, lung cancer	
12	47	Mother, uterine cancer	
13	40		P aunt, colon cancer P uncle, colon cancer
Control			
14	46	Brother, testicular cancer	M grandmother, uterine cancer

^aIn seven individuals, data were available from self-administered questionnaires, and in six individuals by reviewing the medical chart with confirmation by a phone call. In individual no. 8 data were not available. M, maternal; P, paternal.

Table 4 Identified *Cyp19* sequence variants and their frequencies among cases with the high-risk genotype and controls with the low-risk genotype

	Cases with the high-risk genotype (5–13 tested) ^a	Controls with the low-risk genotype (five tested)
Sequence variants in coding exons		
Exon 3	(13 tested)	(Five tested)
G→A at Val80	AA, 1.0	GG, 1.0
Exon 7	(Nine tested ^b)	(Five tested)
C→T in codon 264 (Arg→Cys264)	CC, 0.9 / CT, 0.1	CC, 1.0
Variants in non-coding regions		
5' Region to exon 1.1	(Five tested)	(Five tested)
G→A at – 483 bp to exon 1.1 start	GG, 0.6 / GA, 0.2 / AA, 0.2	GG, 0.8 / GA, 0.2
5' Region to exon 1.1	(12 tested)	(Five tested)
C→T at – 41 bp to exon 1.1 start	CC, 0.66 / CT, 0.17 / TT, 0.17	CC, 0.8 / CT, 0.2
Intron 4	(Five tested)	(Five tested)
TTTA repeats at intron 4	Short repeat ^c	Long repeat ^c
Intron 5	(12 tested)	(Five tested)
G→T at – 16 bp to exon 6 start	TT, 0.6 / GT, 0.4	GT, 0.2 / GG, 0.8
Intron 6	(12 tested)	(Five tested)
T→A at + 36 bp to intron 6 start	AA, 0.6 / TA, 0.4	TA, 0.2 / TT, 0.8
Intron 7	(Nine tested ^d)	(Five tested)
C→T at + 26 bp to intron 7 start	CC, 0.1 / CT, 0.2 / TT, 0.7	CC, 1.0
3' UTR	(11 tested)	(Five tested)
T→C at + 19 bp to intron 10 start	CC, 0.6 / TC, 0.4	TC, 0.2 / TT, 0.8
3' UTR	(11 tested)	(Five tested)
G→T at + 162 bp to intron 10 start	GG, 0.2 / GT, 0.35 / TT, 0.45	GG, 0.8 / GT, 0.2
3' UTR	(Five tested)	(Five tested)
T→C at + 1294 to intron 10 start	TT, 1.0	TT, 0.6 / TC, 0.4

^aThe 12 cases and one control carrying the high-risk genotype are reported together because they displayed the same sequence variants. ^bAdditionally, one CC homozygote and three CT heterozygotes were observed among high-risk cases for which sequencing results could be obtained in only one direction. ^cThe sequencing results for exon 4 and its 3' flanking region indicated that allele 2 would produce a 171-bp product and allele 5 a 187-bp product. ^dTwo additional CC homozygotes and two CT heterozygotes were observed among high-risk cases for which sequencing results could be obtained in only one direction.

STRP genotype and in none of the low-risk controls (Figure 3). The second, a heterozygous state for C→T in exon 7 (Arg→Cys264), appeared in one of nine high-risk cases sequenced in both directions, and in three of four additional high-risk cases with sequencing results obtained in only one direction (frequency of 0.1–0.3 among high-risk cases). All other identified variants were in non-translated regions of the *Cyp19* gene. Of note, in concordance with the results of the automated electrophoresis genotyping analysis, the sequencing results for exon 4 and its 3' flanking region indicated that allele 2 would produce a 171-bp product and allele 5 a 187-bp product.

The 168-bp and 187-bp alleles were the most common alleles in the study population. While the latter (together with the low-risk 191-bp allele) was found to be associated with G in Val80, we elected to check this region in individuals carrying the 168-bp STRP allele. By sequencing ten individuals homozygous for the 168-bp allele (five cases and five controls), we found all to be homozygous for G in codon Val80.

DISCUSSION

Our study examined the association of constitutional genetic variation in the human aromatase gene (*Cyp19*) with breast cancer

occurrence among Caucasian women in the greater Philadelphia region. Our cases population displayed typical features of non-selected cases with invasive breast cancer diagnosed in the United States during the study period, both in tumour characteristics and family history (see Patients and methods section). By typing close to 1000 chromosomes, we were able to identify eight alleles in the study population, sizes ranging from 168 bp to 195 bp [Polymeropoulos et al (1991) identified five alleles sized 154–178 bp, on a typing of only 46 chromosomes]. To facilitate future replicative studies, accurate allele sizes were determined by typing 78 samples using fluorescence-based, automated electrophoresis, and confirmed the allele's transmission in co-dominant segregation in 12 CEPH families.

Contingency table analysis revealed a statistically significant difference in allelic distribution between cases and controls. Specifically, the 171-bp allele was over-represented in cases, and the 191-bp allele was more common in controls. All but one of 14 individuals homozygous for the 171-bp allele were cases. Though not formally significant, these homozygous cases were diagnosed at a younger mean and median age than the total cases' group, and displayed a remarkably high incidence of breast and other cancers in their family histories. Preliminary data in African-American women show over-representation of individuals homozygous for

the 171-bp allele in cases with breast cancer (5 out of 13 cases; one out of eight controls). These results provide additional support for the suggestion that constitutional genetic variation at or near the *Cyp19* locus is associated with the risk of developing breast cancer, with the 171-bp allele serving as the high-risk allele or at least its surrogate.

Our DNA sequencing efforts focused on the coding regions of the *CYP19* locus and the major non-translated exons I controlling its expression in adipose, ovarian and placental tissues. It included the non-translated exons I, which control aromatase expression in normal breast adipocytes (exon I.4) and during malignant breast transformation (exon I.3 and promoter II). By analysing sequences obtained for individuals with the high-risk genotypes (homozygous for the 171-bp allele) and controls with the putative low-risk genotypes (heterozygous for the 187-/191-bp alleles), we identified several common nucleotide variants. Of particular interest is the silent variation in exon 3 (G→A, Val80), which was observed to be in complete association with the high-risk genotype and was not observed in 15 sampled individuals carrying the common alleles (168-bp and 187-bp alleles) or the low-risk allele (191 bp allele). Further studies should assess its occurrence in a larger population of cases and controls, and test whether this variant can affect aromatase activity by modifying *Cyp19*RNA splicing or stability. This variant was previously observed by Sourdain et al (1994) in genomic DNA from two breast tumours selected for insensitivity to the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA), but not in two other breast tumours showing slightly lower basal aromatase activity and sensitivity to inhibition by 4-OHA. Sourdain et al (1994) also observed the T→C variant at +19 to intron 10 start in the two resistant tumours (which in our work was more common among controls carrying the low-risk genotype), and a heterozygous state for the exon 7 C→T (Arg→Cys264) in only one of them. A fifth breast tumour evaluated by Sourdain et al (1994), with no detectable aromatase activity, did not show any of the sequence variants detected in the tumours resistant to 4-OHA. Sourdain et al (1994) identified no other coding region sequence variants in any of the breast tumours; the intron 4 STRP region and the non-translated regulatory exons I were not evaluated in their work. Taken together with our work, it is possible to theorize that the G→A variant in codon Val80, which occurred in complete association with the high-risk STRP genotype, is related to the phenotype of slightly elevated basal aromatase activity with resistance to inhibition by 4-OHA. However, only direct analysis addressing the effects of G→A (Val80) variation on aromatase expression in the breast can prove it, especially considering that Sourdain et al (1994) selected the breast tumours in their work by their response to inhibition by 4-OHA and not their baseline aromatase activity.

Another possibility is that the intron 4 STRP itself produces an intrinsic effect on aromatase expression. Triplet repeat variations in non-coding regions of the *FMRI* gene and *MK-PK* gene are known to result in fragile X syndrome and myotonic dystrophy respectively (Fu et al, 1991; Verkerk et al, 1991; Brook et al, 1992; Mahadevan et al, 1992; Kunst and Warren, 1994). Constitutional genetic variation in variable tandem repeats located some 1000 bp downstream from the coding region of the *H-RAS1* proto-oncogene have been shown to be associated with cancer risk in case-control studies (Krontiris et al, 1985, 1993). Functional studies have also suggested that the variable tandem repeats themselves might interact with transcription factors affecting expression of associated genes, or might alter RNA stability (Green and

Krontiris, 1993; Trepicchio and Krontiris, 1993; Kennedy et al, 1995). Finally, it is possible that the high-risk STRP allele is associated with a novel breast-specific exon I not yet described. Recently, Stratakis et al (1996) reported a family with a transmitted phenotype of increased aromatase activity, which was observed to be associated with a specific STRP variant and a novel non-translated exon I. This finding implies the existence of an as-yet-unidentified variation in the 5' flanking sequence, which controls aromatase expression and is associated with the high-risk STRP variant.

In BALB/cD2 mice, integration of the mouse mammary tumour virus to the *Int5* locus (located at the 3' UTR of mouse *Cyp19* gene) resulted in up-regulation of the aromatase gene; it was associated with the development of preneoplastic mammary tumours (Durgam and Tekmal, 1994; Tekmal and Durgam, 1995). In female Sprague-Dawley rats, treatment with the aromatase inhibitor fadrozole hydrochloride prevented the appearance of spontaneous benign and malignant mammary tumours (Gunson et al, 1995). Understanding the biological significance of the human high-risk allele may lead to prevention of breast cancer in high-risk individuals identified by *Cyp19* genotyping.

In conclusion, our study shows a significant difference in constitutional genetic variation at intron 4 of the human *Cyp19* gene between cases and controls (Caucasian women). We identified a high-risk allele at this locus, although its biological significance has yet to be determined. Confirmatory studies are necessary to conclude that *Cyp19* genotyping can conclusively identify women at an increased risk for developing breast cancer. Ultimately, it is our hope that an understanding of the biological significance of the high-risk allele will bring us closer to a medical prevention of breast cancer, in which high-risk individuals identified with *Cyp19* genotyping are offered specific treatment affecting aromatase activity.

ACKNOWLEDGEMENTS

This work is supported by an ASCO Young Investigator Award sponsored by Zeneca, a clinical investigator training grant CA01728 and a pilot project on a cancer genetics supplement to USPHS Institutional core grant CA06927 from the National Institutes of Health (to Dr Siegelmann-Danieli), and by an appropriation from the Commonwealth of Pennsylvania.

The authors acknowledge Katherine A. McGlynn PhD for kindly reviewing the manuscript, Michael N. Edmonson for analytical assistance and John Q Zhang and for technical assistance.

REFERENCES

- Agarwal VR, Bulun SE, Leitch M, Rohrich R and Simpson ER (1996) Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. *J Clin Endocrinol Metab* **81**: 3843–3849
- American Joint Committee on Cancer (1992) Manual for staging of cancer, 4th edn. In *Breast*, pp. 149–154. JB Lipincott: Philadelphia
- Berrino F, Muti P, Micheli A, Gianfranco B, Krogh V, Sciajno R, Pisani P, Panico S and Secreto G (1996) Serum sex hormone levels after menopause and subsequent breast cancer. *J Natl Cancer Inst* **88**: 291–296
- Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T, Sohn R, Zelman B, Snell RG, Rundle SA, Crow S, Davies J, Shelbourne P, Buxton J, Jones C, Juvonen V, Johnson K, Harper PS, Shaw DJ and Housman DE (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell* **68**: 799–808

- Buetow KH (1996) Genetic mapping. In *Current Protocols in Human Genetics*. Dracopoli N, Haines JL, Korf BR, Morton CC, Seidman CE, Seidman JG, Moir DT and Smith D (eds.), section 1, pp. 1.0.1–1.10.8. John Wiley & Sons: Brooklyn, NY
- Bulun SE and Simpson ER (1994) Regulation of aromatase expression in human tissues. *Breast Cancer Res Treat* **30**: 19–29
- Chen S, Besman MJ, Sparkes RS, Zollman S, Klisak I, Mohandas T, Hall PF and Shively JE (1988) Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. *DNA* **7**: 27–38
- Conte FA, Grumbach MM, Ito Y, Fisher CR and Simpson ER (1994) A syndrome of female pseudohermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). *J Clin Endocrinol Metab* **78**: 1287–1292
- Corbin CJ, Graham-Lorence S, McPhaul M, Mason Ji, Mendelson CR and Simpson ER (1988) Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. *Proc Natl Acad Sci USA* **85**: 8948–8952
- Durgam VR and Tekmal RR (1994) The nature and expression of *int-5*, a novel MMTV integration locus gene in carcinogen-induced mammary tumors. *Cancer Lett* **87**: 179–186
- Fu Y-H, Kuhl DPA, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJMH, Holden JJA, Fenwick RGJ, Warren ST, Oostra BA, Nelson DL and Caskey CT (1991) Variation of the CGG repeat at the fragile X site. Results in genetic instability: resolution of the Sherman Paradox. *Cell* **67**: 1047–1058
- Green M and Krontiris TG (1993) Allelic variation of reporter gene activation by the HRAS1 minisatellite. *Genomics* **17**: 429–434
- Gunson DE, Steele RE and Chau RY (1995) Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. *Br J Cancer* **72**: 72–75
- Harada N (1988) Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. *Biochem Biophys Res Commun* **156**: 725–732
- Harada N, Yamada K, Saito K, Kibe N, Dohmae S and Takagi Y (1990) Structural characterization of the human estrogen synthetase (aromatase) gene. *Biochem Biophys Res Commun* **166**: 365–372
- Harada N, Ogawa H, Shozu M, Yamada K, Suhara K, Nishida E and Takagi Y (1992) Biochemical and molecular genetic analyses on placental aromatase (P450Arom) deficiency. *J Biol Chem* **267**: 4781–4785
- Harada N, Utsumi T and Takagi Y (1993) Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. *Proc Natl Acad Sci USA* **90**: 11312–11316
- Honda S, Harada N and Takagi Y (1994) Novel exon 1 of the aromatase gene specific for aromatase transcripts in human brain. *Biochem Biophys Res Commun* **198**: 1153–1160
- James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW and Reed MJ (1987) Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. *Steroids* **50**: 269–279
- Kennedy GC, German MS and Rutter WJ (1995) The minisatellite in the diabetes susceptibility locus *IDDM2* regulates insulin transcription. *Nature Genet* **9**: 293–298
- Krontiris TG, DiMartino NA, Colb M and Parkinson D (1985) Unique allelic restriction fragments of the human Ha-ras locus in leukocytes and tumor DNAs of cancer patients. *Nature* **313**: 369–374
- Krontiris TG, Delvin B, Karp D, Robert NJ and Risch N (1993) An association between risk of cancer and mutations in the HRAS1 minisatellite locus. *N Engl J Med* **329**: 517–523
- Kunst KB and Warren ST (1994) Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. *Cell* **77**: 853–861
- Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcelo J, O'Hoy K, Leblond S, Earle-Macdonald J, De Jong PJ, Wieringa B and Korneluk RG (1992) Myotonic dystrophy mutation: an unstable CTTG repeat in the 3' untranslated region of the gene. *Science* **255**: 1253–1258
- Mahendroo MS, Mendelson CR and Simpson ER (1993) Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. *J Biol Chem* **268**: 19463–19470
- Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR and Simpson ER (1989) Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. *J Biol Chem* **264**: 19385–19391
- Means GD, Kilgore MW, Mahendroo MS, Mendelson CR and Simpson ER (1991) Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. *Mol Endocrinol* **5**: 2005–2013
- Mendelson CR, Means GD, Mahendroo ML, Corbin CJ, Steinkampf MP, Graham-Lorence S and Simpson ER (1990) Use of molecular probes to study regulation of aromatase cytochrome P-450. *Biol Reprod* **42**: 1–10
- Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* **16**: 1215
- Polymeropoulou MH, Xiao H, Rath DS and Merrill CR (1991) Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). *Nucleic Acids Res* **19**: 195
- Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM and Reed MJ (1995) Aromatase activity and interleukin-6 production by normal and malignant breast tissues. *J Clin Endocrinol Metab* **80**: 3052–3058
- Ries LA, Miller BA, Hankey BF, Kosary CL, Hargis A and Edwards BK (1994) 1973–1991 Tables and graphs, National Cancer Institute. In *SEER Cancer Statistics Review*, p. 128. Publication no. 94-2789. NIH: Bethesda, MD
- Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafer L, Zaino R and Santner SJ (1994) Stromal spindle cells contain aromatase in human breast tumors. *J Clin Endocrinol Metab* **79**: 627–632
- Sasano H, Nagura H, Harada N, Goukon Y and Kimura M (1994) Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. *Hum Pathol* **25**: 530–535
- Schmidt M and Löffler G (1994) The human breast cancer cell line MDA-MB231 produces an aromatase stimulating activity. *Eur J Cell Biol* **63**: 96–101
- Sourdaine P, Parker MG, Telford J and Miller WR (1994) Analysis of the aromatase cytochrome P450 gene in human breast tumors. *J Mol Endocrinol* **13**: 331–337
- Stratakis CA, Vottero A, Brodie A, DeArkie D, Lu O, Mitsiades CS, Meada T, Yamamoto Y, Sagara Y, Ikeda H and Shizuta Y (1996) Biochemical and molecular genetics of the syndrome of increased aromatase activity: segregation with a marker from within the P450arom gene and evidence for aberrant alternative splicing of its 5'-end mRNA. *Am J Hum Genet* **59**: A43
- Tan L and Muto N (1986) Purification and reconstitution properties of human placental aromatase. A cytochrome P450-type monooxygenase. *Eur J Biochem* **156**: 243–250
- Tekmal RR and Durgam VR (1995) The overexpression of *int-5/Aromatase*, a novel MMTV integration locus gene, is responsible for D2 mammary tumor cell proliferation. *Cancer Lett* **88**: 147–155
- Toda K and Shizuta Y (1993) Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450. *Eur J Biochem* **213**: 383–389
- Toda K, Terashima M, Kawamoto T, Sumimoto H, Yokoyama Y, Kuribayashi I, Mitsuchi Y, Yue W, Flor AW, Gamica A, Mitsiades CS and Chrousos GP (1990) Structural and functional characterization of human aromatase P-450 gene. *Eur J Biochem* **193**: 559–565
- Toda K, Yang L-X and Shizuta Y (1995) Transcriptional regulation of the human aromatase cytochrome P450 gene expression in human placental cells. *J Steroid Biochem Mol Biol* **53**: 181–190
- Trepicchio WL and Krontiris TG (1993) *IGH* minisatellite suppression of USF-binding-site- and Em-mediated transcriptional activation of the adenovirus major late promoter. *Nucleic Acids Res* **21**: 977–985
- Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van Ommen BJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey T, Nelson DL, Oostra BA and Warren ST (1991) Identification of a gene (*FMR-1*) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell* **65**: 905–914
- Utsumi T, Harada N, Maruta M and Takagi Y (1996) Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. *J Clin Endocrinol Metab* **81**: 2344–2349
- Zhao Y, Mendelson CR and Simpson ER (1995) Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. *Mol Endocrinol* **9**: 340–349
- Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S and Chen S (1996a) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. *J Steroid Biochem Mol Biol* **49**: 163–171
- Zhou D, Clarke P, Wang J and Chen S (1996b) Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. *J Biol Chem* **271**: 15194–15202